keyword
MENU ▼
Read by QxMD icon Read
search

Rotigotine

keyword
https://www.readbyqxmd.com/read/28273839/parkinson-s-disease-from-pathogenesis-to-pharmacogenomics
#1
REVIEW
Ramón Cacabelos
Parkinson's disease (PD) is the second most important age-related neurodegenerative disorder in developed societies, after Alzheimer's disease, with a prevalence ranging from 41 per 100,000 in the fourth decade of life to over 1900 per 100,000 in people over 80 years of age. As a movement disorder, the PD phenotype is characterized by rigidity, resting tremor, and bradykinesia. Parkinson's disease -related neurodegeneration is likely to occur several decades before the onset of the motor symptoms. Potential risk factors include environmental toxins, drugs, pesticides, brain microtrauma, focal cerebrovascular damage, and genomic defects...
March 4, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28258926/corrigendum-to-rotigotine-transdermal-patch-in-chinese-patients-with-early-parkinson-s-disease-a-randomized-double-blind-placebo-controlled-pivotal-study-park-relat-disord-28-2016-49-55
#2
Zhen-Xin Zhang, Hui-Fang Shang, Xingyue Hu, Shengdi Chen, Zhongxin Zhao, Xinlu Du, Erwin Surmann, Lars Bauer, Mahnaz Asgharnejad
No abstract text is available yet for this article.
February 24, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28222651/levodopa-placebo-and-rotigotine-change-biomarker-levels-for-oxidative-stress
#3
Siegfried Muhlack, Manuel Kinkel, Lennard Herrman, Thomas Müller
INTRODUCTION: Homocysteine increase and glutathione derivative cysteinyl-glycine fall are indirect biomarkers for oxidative stress, for instance due to dopamine D1 receptor stimulation. OBJECTIVES: To investigate the influence of the D1 receptor agonists levodopa and rotigotine compared with placebo on homocysteine and cysteinyl-glycine in plasma of patients with Parkinson's disease. METHODS: Patients received 100 mg levodopa, 4 mg rotigotine or placebo...
February 22, 2017: Neurological Research
https://www.readbyqxmd.com/read/28168729/novel-uhplc-ms-ms-method-for-the-determination-of-rotigotine-in-the-plasma-of-patients-with-parkinson-s-disease
#4
Susan Mohamed, Roberto Riva, Manuela Contin
A novel ultra high pressure liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of the dopamine receptor agonist rotigotine in human plasma. Following liquid-liquid extraction with tert-butyl methyl ether from 500 μL plasma, the chromatographic analysis was performed on a Gemini NX3 column using 5 mM pH 5.0 ammonium acetate/5 mM ammonium acetate in methanol as binary gradient mobile phase, at a flow rate of 0.3 mL/min. The MS/MS ion transitions were 316...
February 6, 2017: Biomedical Chromatography: BMC
https://www.readbyqxmd.com/read/28148284/rasagiline-induced-severe-recurrent-hypoglycemia-in-a-young-woman-without-diabetes-a-case-report
#5
Fawzi A Bachet Ibrahim, Fauzia Rashid, Azza A Bin Hussain, Fatheya Alawadi, A Bashier
BACKGROUND: We report a case of a patient with recurrent severe hypoglycemia after initiating the drug rasagiline (Azilect) for Parkinson disease. CASE PRESENTATION: A 25-year-old Emirati woman who had been diagnosed with Parkinson disease due to a genetic mutation since the age of 18 years presented to our hospital. She had been treated with a rotigotine patch 2 mg per day along with carbidopa + levodopa + entacapone 25 mg/100 mg/200 mg (Stalevo) over these years...
February 2, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27998652/the-need-for-non-oral-therapy-in-parkinson-s-disease-a-potential-role-for-apomorphine
#6
Teus van Laar, Robbert Borgemeester
In the course of Parkinson's disease (PD), oral medication may lose its effectiveness due to several reasons, like dysphagia, impaired absorption from the gastro-intestinal tract and delayed emptying of the stomach. If these problems occur, a non-oral therapy should be considered. Examples of non-oral therapies are transdermal patches, (e.g. rotigotine) which may overcome motor and nonmotor nighttime problems, and may serve as well to treat daytime response-fluctuations, if oral therapies fail to do so. Other options are injections with apomorphine to treat early morning dystonia and random off-periods during daytime, as well as continuously infused subcutaneous apomorphine for random fluctuations in PD patients...
December 2016: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/27994458/intranasal-delivery-of-rotigotine-to-the-brain-with-lactoferrin-modified-peg-plga-nanoparticles-for-parkinson-s-disease-treatment
#7
Chenchen Bi, Aiping Wang, Yongchao Chu, Sha Liu, Hongjie Mu, Wanhui Liu, Zimei Wu, Kaoxiang Sun, Youxin Li
Sustainable and safe delivery of brain-targeted drugs is highly important for successful therapy in Parkinson's disease (PD). This study was designed to formulate biodegradable poly(ethylene glycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs), which were surface-modified with lactoferrin (Lf), for efficient intranasal delivery of rotigotine to the brain for the treatment of PD. Rotigotine NPs were prepared by nanoprecipitation, and the effect of various independent process variables on the resulting properties of NPs was investigated by a Box-Behnken experimental design...
2016: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/27941527/striatal-dopamine-transporter-modulation-after-rotigotine-results-from-a-pilot-single-photon-emission-computed-tomography-study-in-a-group-of-early-stage-parkinson-disease-patients
#8
Carlo Rossi, Dario Genovesi, Paolo Marzullo, Assuero Giorgetti, Elena Filidei, Giovanni Umberto Corsini, Ubaldo Bonuccelli, Roberto Ceravolo
INTRODUCTION: Several in vitro data have reported negative interference by dopamine-agonists on the expression of dopamine transporter (DAT), whereas the majority of imaging studies have shown that neither L-dopa nor dopamine-agonists interfere with DAT availability. As yet, there are no in vivo studies on DAT expression after treatment with rotigotine. METHODS: We evaluated presynaptic nigrostriatal function in 8 patients with de novo Parkinson disease (age, 59 ± 6...
January 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/27883297/patients-perception-of-parkinson-s-disease-associated-pain-following-initiation-of-rotigotine-a-multicenter-non-interventional-study
#9
MULTICENTER STUDY
Lars Timmermann, Christian Oehlwein, Gerhard Ransmayr, Holger Fröhlich, Edgar Will, Hanna Schroeder, Thomas Lauterbach, Lars Bauer, Jan Kassubek
OBJECTIVES: To evaluate Parkinson's disease (PD)-associated pain as perceived by the patients (subjective characterization), and how this may change following initiation of rotigotine transdermal patch. METHODS: SP1058 was a non-interventional study conducted in routine clinical practice in Germany and Austria in patients experiencing PD-associated pain (per the physician's assessment). Data were collected at baseline (ie, before rotigotine initiation) and at a routine visit after ≥25 days (-3 days allowed) of treatment on a maintenance dose of rotigotine (end of study [EoS])...
January 2017: Postgraduate Medicine
https://www.readbyqxmd.com/read/27870257/higher-levels-of-apomorphine-and-rotigotine-prescribing-reduce-overall-secondary-healthcare-costs-in-parkinson-s-disease
#10
A H Heald, M Livingston, M Stedman, Z Wyrko
BACKGROUND: Parkinson's disease (PD) affects around 100,000 people in England. A number of non-oral therapies can improve both the quality of life and reduce patient needs for health and social care. However, these can be relatively expensive at £2000-£10,000 per year per patient. Our aim was to examine how prescribing of these agents relates to secondary care costs. METHODS: Using practice level primary care prescribing data and hospital episode statistical data in England, we investigated the relation between general practitioner prescriptions of apomorphine injections/rotigotine patches and the secondary care costs accrued for their diagnosed PD patients for 2011-2014...
November 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27856776/practice-guideline-summary-treatment-of-restless-legs-syndrome-in-adults-report-of-the-guideline-development-dissemination-and-implementation-subcommittee-of-the-american-academy-of-neurology
#11
John W Winkelman, Melissa J Armstrong, Richard P Allen, K Ray Chaudhuri, William Ondo, Claudia Trenkwalder, Phyllis C Zee, Gary S Gronseth, David Gloss, Theresa Zesiewicz
OBJECTIVE: To make evidence-based recommendations regarding restless legs syndrome (RLS) management in adults. METHODS: Articles were classified per the 2004 American Academy of Neurology evidence rating scheme. Recommendations were tied to evidence strength. RESULTS AND RECOMMENDATIONS: In moderate to severe primary RLS, clinicians should consider prescribing medication to reduce RLS symptoms. Strong evidence supports pramipexole, rotigotine, cabergoline, and gabapentin enacarbil use (Level A); moderate evidence supports ropinirole, pregabalin, and IV ferric carboxymaltose use (Level B)...
December 13, 2016: Neurology
https://www.readbyqxmd.com/read/27810181/a-method-to-switch-from-oral-dopamine-agonists-to-rotigotine-in-patients-with-restless-legs-syndrome-and-mild-augmentation
#12
John W Winkelman, Susan E Mackie, Leslie A Mei, Samuel Platt, Laura Schoerning
BACKGROUND: We examined the short- and long-term efficacy and tolerability of a cross-titration algorithm from oral dopamine agonists to the rotigotine transdermal patch in patients dissatisfied with their restless legs syndrome (RLS) treatment, predominantly with mild augmentation. METHODS: Patients with RLS (n = 20) were recruited at a single site. The cross-titration consisted of decreasing oral dopaminergic agents (ropinirole by 1 mg or pramipexole by 0...
August 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27796464/ergot-and-non-ergot-dopamine-agonists-and-heart-failure-in-patients-with-parkinson-s-disease
#13
François Montastruc, Florence Moulis, Mélanie Araujo, Leila Chebane, Olivier Rascol, Jean-Louis Montastruc
PURPOSE: Some studies have suggested a potential risk of heart failure in patients with Parkinson's disease receiving dopamine (DA) agonists. However, the results are conflicting. We used VigiBase®, the World Health Organization (WHO) Global Individual Case Safety Reports (ICSRs) database, to investigate a potential signal strengthening of heart failure with DA agonists in Parkinsonian patients older than 45 years. METHODS: A case/non-case (disproportionality) analysis was performed in Vigibase® using ICSRs registered between 1978 and May 2016...
January 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27726069/an-observational-clinical-and-video-polysomnographic-study-of-the-effects-of-rotigotine-in-sleep-disorder-in-parkinson-s-disease
#14
Yan Wang, Yue-Chang Yang, Dan-Mei Lan, Hui -Juan Wu, Zhong-Xin Zhao
PURPOSE: Sleep disturbance is common in Parkinson's disease (PD) and negatively impacts quality of life. There is little data on how dopamine agonists influence nocturnal sleep in PD, particularly in sleep laboratory data to measure sleep parameters and their changes objectively. The goal of this open-label study was to objectively evaluate the effect of rotigotine on sleep in PD patients by video-polysomnographic methods. METHODS: A total of 25 PD patients with complaints of nocturnal sleep impairment were enrolled...
October 11, 2016: Sleep & Breathing, Schlaf & Atmung
https://www.readbyqxmd.com/read/27725534/transdermal-patch-of-rotigotine-attenuates-freezing-of-gait-in-patients-with-parkinson-s-disease-an-open-label-comparative-study-of-three-non-ergot-dopamine-receptor-agonists
#15
COMPARATIVE STUDY
Ken Ikeda, Takehisa Hirayama, Takanori Takazawa, Kiyokazu Kawabe, Yasuo Iwasaki
Objective Parkinson's disease (PD) is characterized by the progressive degeneration of the nigrostriatal dopaminergic neurons. Rotigotine is a non-ergot dopamine receptor agonist (DA). Its transdermal patch maintains the effective concentrations for 24 hours. Freezing of gait (FOG) is a common and devastating symptom in PD patients. Little is known about therapeutic effects of rotigotine on FOG in PD patients. Herein we compared how three non-ergot DAs of rotigotine, pramipexole LA and ropinirole CR influence FOG, besides classical motor deficits in PD patients...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27629973/restless-bladder-in-an-elderly-woman-an-unusual-feature-or-a-variant-of-restless-legs-syndrome
#16
Keisuke Suzuki, Masayuki Miyamoto, Tomoyuki Uchiyama, Tomoyuki Miyamoto, Takeo Matsubara, Koichi Hirata
We herein report an elderly patient with a history of restless legs syndrome (RLS) who developed unpleasant sensations in the lower abdomen and perineum. The patient' s symptoms occurred during the evening and at rest and forced the patient to void, resulting in some symptom relief. Urological examinations and spinal magnetic resonance imaging findings were unremarkable. The adjunctive use of rotigotine resolved her symptoms. The symptoms were considered to be "restless bladder". Further studies are required to elucidate whether restless bladder is an identical condition to the clinical entities of other RLS variants or whether it represents an unusual feature of RLS...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27568909/effects-of-rotigotine-on-rem-sleep-behavior-disorder-in-parkinson-disease
#17
Yan Wang, Yuechang Yang, Huijuan Wu, Danmei Lan, Ying Chen, Zhongxin Zhao
STUDY OBJECTIVES: REM sleep behavior disorder (RBD) is a common manifestation of Parkinson disease (PD). In this study, we assessed the effects of rotigotine transdermal patch on RBD features in patients with PD. METHODS: In this prospective open-label study, eleven PD patients with untreated RBD were administered rotigotine patches for up to seven months to ameliorate their parkinsonism. The severities of their RBD symptoms before and after rotigotine therapy were evaluated through patient and bed partner interviews, a validated evaluation scale (REM sleep behavior disorder questionnaire-Hong Kong, RBDQ-HK), and blinded assessments based on video-polysomnographic (VPSG) measure...
October 15, 2016: Journal of Clinical Sleep Medicine: JCSM: Official Publication of the American Academy of Sleep Medicine
https://www.readbyqxmd.com/read/27567886/efficacy-of-rotigotine-at-different-stages-of%C3%A2-parkinson-s-disease-symptom-severity-and-disability-a-post-hoc-analysis-according-to-baseline-hoehn-and-yahr-stage
#18
Nir Giladi, Anthony P Nicholas, Mahnaz Asgharnejad, Elisabeth Dohin, Franz Woltering, Lars Bauer, Werner Poewe
BACKGROUND: The efficacy of rotigotine has been demonstrated in studies of patients with early (i.e. not receiving levodopa) and advanced (i.e. not adequately controlled on levodopa; average 2.5 h/day in 'off' state) Parkinson's disease (PD). OBJECTIVE: To further investigate the efficacy of rotigotine transdermal patch across different stages of PD symptom severity and functional disability, according to baseline Hoehn and Yahr (HY) staging. METHODS: Post hoc analysis of six placebo-controlled studies of rotigotine in patients with early PD (SP506, SP512, SP513; rotigotine ≤8 mg/24 h) or advanced-PD (CLEOPATRA-PD, PREFER, SP921; rotigotine ≤16 mg/24 h)...
October 19, 2016: Journal of Parkinson's Disease
https://www.readbyqxmd.com/read/27448485/rotigotine-may-improve-sleep-architecture-in-parkinson-s-disease-a-double-blind-randomized-placebo-controlled-polysomnographic-study
#19
Mariangela Pierantozzi, Fabio Placidi, Claudio Liguori, Maria Albanese, Paola Imbriani, Maria Grazia Marciani, Nicola Biagio Mercuri, Paolo Stanzione, Alessandro Stefani
BACKGROUND/OBJECTIVES: Growing evidence demonstrates that in Parkinson's Disease (PD) sleep disturbances are frequent and difficult to treat. Since the efficacy of rotigotine on sleep is corroborated by studies lacking polysomnography (PSG), this study explores the possible rotigotine-mediated impact on PSG parameters in PD patients. METHODS: This is a randomized, double-blind, placebo-controlled, parallel-group study to determine the efficacy of rotigotine vs placebo on PSG parameters in moderately advanced PD patients...
May 2016: Sleep Medicine
https://www.readbyqxmd.com/read/27448465/guidelines-for-the-first-line-treatment-of-restless-legs-syndrome-willis-ekbom-disease-prevention-and-treatment-of-dopaminergic-augmentation-a-combined-task-force-of-the-irlssg-eurlssg-and-the-rls-foundation
#20
Diego Garcia-Borreguero, Michael H Silber, John W Winkelman, Birgit Högl, Jacquelyn Bainbridge, Mark Buchfuhrer, Georgios Hadjigeorgiou, Yuichi Inoue, Mauro Manconi, Wolfgang Oertel, William Ondo, Juliane Winkelmann, Richard P Allen
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation...
May 2016: Sleep Medicine
keyword
keyword
56686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"